BeiGene Ltd Ordinary Shares 06160
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if 06160 is a good fit for your portfolio.
News
-
BeiGene Receives FDA Approval for TEVIMBRA® for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy
-
First Doses of BRUKINSA® provided to Patients with Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries Under Collaboration of The Max Foundation, BeiGene, and the BeiGene Foundation
-
BeiGene Announces FDA Accelerated Approval of BRUKINSA for the Treatment of Relapsed or Refractory Follicular Lymphoma
-
BeiGene to Present Clinical and Preclinical Data from Broad Portfolio and Pipeline at AACR Annual Meeting 2024
-
BeiGene Announces New Efficacy Analysis Comparing BRUKINSA® vs Acalabrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
-
BeiGene to Present at Upcoming Investor Conferences
-
BeiGene’s Biologics License Application for TEVIMBRA® (tislelizumab) for First-Line Gastric or Gastroesophageal Junction Cancers Accepted by FDA
-
BeiGene Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
Trading Information
- Previous Close Price
- HKD 84.00
- Day Range
- HKD 81.50–83.85
- 52-Week Range
- HKD 81.50–164.10
- Bid/Ask
- HKD 82.10 / HKD 82.35
- Market Cap
- HKD 111.52 Bil
- Volume/Avg
- 1.0 Mil / 1.5 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 6.57
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
BeiGene Ltd is a commercial-stage biotechnology company. It is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The company has developed a proprietary cancer biology platform that addresses the importance of tumor-immune system interactions and the value of primary biopsies in developing new models to support its drug discovery effort. It has developed clinical-stage drug candidates that inhibit the important oncology targets Bruton's tyrosine kinase, or BTK; RAF dimer protein complex and PARP family of proteins, and an immuno-oncology agent that inhibits the immune checkpoint protein receptor PD-1. Its geographical segments are China, the United States, and the Rest of the world.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Large Growth
- Total Number of Employees
- 10,000
- Website
- https://www.beigene.com
Comparables
Valuation
|
Metric
|
06160
|
09688
|
09939
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 4.58 | 2.01 | 0.83 |
Price/Sales | 6.57 | 5.95 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
06160
|
09688
|
09939
|
|---|---|---|---|
Quick Ratio | 1.97 | 4.29 | 2.66 |
Current Ratio | 2.32 | 4.63 | 4.89 |
Interest Coverage | — | — | −54.22 |
Quick Ratio
06160
09688
09939
Profitability
|
Metric
|
06160
|
09688
|
09939
|
|---|---|---|---|
Return on Assets (Normalized) | −8.47% | −22.36% | −29.60% |
Return on Equity (Normalized) | −12.68% | −26.78% | −42.85% |
Return on Invested Capital (Normalized) | −12.45% | −30.45% | −34.63% |
Return on Assets
06160
09688
09939
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Vzlryxmt | Fbw | $559.8 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Pnkdnqb | Yxskqy | $102.5 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Pxslvnhtt | Bhzyth | $98.6 Bil | |
MRNA
| Moderna Inc | Vjyvyyrvw | Zshd | $41.0 Bil | |
ARGX
| argenx SE ADR | Vvrmfsjb | Bhcfm | $22.6 Bil | |
BNTX
| BioNTech SE ADR | Jkvtplt | Rthv | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Ftygdhvf | Qcqjvb | $18.8 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Xppwwvt | Jlsdb | $17.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Qpljmpvjd | Gmmtxpd | $12.6 Bil | |
INCY
| Incyte Corp | Lcqttcdt | Vjblt | $12.0 Bil |